And despite lack of statistical significance, results of the trial which assessed the efficacy of addition of bevacizumab to erlotinib also suggested that patients with EGFR-mutant tumours may benefit from the combined inhibition therapy (median OS: 18 months for bevacizumab plus erlotinib vs 12 months for erlotinib; HR, 0.44; 95% CI, 0.11–1.67). The gene discussed is EGFR; the disease is neoplasm.